Ratings Alnylam Pharmaceuticals, Inc. Börse Stuttgart

Equities

DUL

US02043Q1076

Real-time Estimate Tradegate Other stock markets 02:53:05 28/06/2024 pm IST			5-day change	1st Jan Change
230.6 ^EUR	-0.15%		+59.42%	+31.55%

27/06	Stifel Adjusts Price Target on Alnylam Pharmaceuticals to $295 From $215, Maintains Buy Rating	MT
27/06	RBC Raises Price Target on Alnylam Pharmaceuticals to $265 From $250, Keeps Outperform Rating	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
The company is in a robust financial situation considering its net cash and margin position.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the past year, analysts have significantly revised downwards their profit estimates.
Over the past twelve months, analysts' opinions have been revised negatively.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ALNYLAM PHARMACEUTICALS, INC.	+31.55%	3.12TCr	-
MODERNA, INC.	+21.85%	4.64TCr	B-
LONZA GROUP AG	+38.76%	3.91TCr	A
IQVIA HOLDINGS INC.	-8.05%	3.88TCr	B
CELLTRION, INC.	-13.75%	2.58TCr	C
ICON PUBLIC LIMITED COMPANY	+10.65%	2.59TCr	B-
MEDPACE HOLDINGS, INC.	+38.43%	1.31TCr	C+
BIO-TECHNE CORPORATION	-6.92%	1.13TCr	B+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.29%	1.07TCr	C+
QIAGEN N.V.	-8.20%	911.79Cr	A

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes